Clinical Trial: A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors

U.S., April 7 -- ClinicalTrials.gov registry received information related to the study (NCT07512063) titled 'A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors' on March 12.

Brief Summary: The aim of this study was to evaluate patient profiles, treatment patterns, and outcomes of hormone receptor positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer (mBC) patients treated with a 1L cyclin dependent kinase 4/6 inhibitor (CDK4/6i) in the real-world setting.

Study Start Date: Oct. 08, 2024

Study Type: OBSERVATIONAL

Condition: Breast Cancer

Recruitment Status: COMPLETED

Sponsor: Novartis Pharmaceutica...